Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Earlier this month, UnitedHealth Group held its 2026 annual shareholder meeting, reported voting results that rejected an independent board chair proposal, and approved a quarterly cash dividend of US$2.32 per share payable on June 23 to shareholders of record on June 15. These governance and capital return decisions arrive as UnitedHealth's Medicare-focused recovery, cost-control progress, and dividend track record are drawing renewed attention from analysts and income-oriented investors. With UnitedHealth's dividend decision underscoring confidence in cash generation, we'll now assess how this shapes the company's existing investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

UnitedHealth Group Investment Narrative Recap

To own UnitedHealth Group today, you need to believe its Medicare-focused recovery, cost controls and diversified Optum platform can support earnings while policy and utilization risks remain front and center. The key near term catalyst is execution on Medicare Advantage repricing and margin repair, while the biggest risk is another surprise uptick in care activity or policy-driven reimbursement pressure. The latest dividend increase and governance vote do not materially change those core drivers.

The most relevant recent announcement is the US$2.32 quarterly dividend, coming as UnitedHealth raises 2026 EPS guidance above US$18.25 and reports improved medical cost ratios in Q1 2026. Together, these updates have sharpened attention on whether margin progress is sustainable just as analysts highlight ongoing DOJ Medicare review risk and the challenges of stabilizing Medicare membership and economics.

Yet beneath the dividend increase and analyst optimism, there are still important Medicare related risks investors should be aware of, including ...

Read the full narrative on UnitedHealth Group (it's free!)

UnitedHealth Group's narrative projects $492.0 billion revenue and $21.4 billion earnings by 2029. This requires 3.0% yearly revenue growth and a $9.4 billion earnings increase from $12.0 billion today.

Uncover how UnitedHealth Group's forecasts yield a $399.73 fair value, in line with its current price.

Exploring Other PerspectivesUNH 1-Year Stock Price Chart

Some of the lowest ranked analysts paint a far tougher picture than the consensus, assuming revenue of about US$460.4 billion and earnings near US$20.2 billion by 2029, and argue that heavy reliance on government programs could keep margins under pressure even if recent Medicare cost improvements and dividend decisions eventually prove supportive.

Story Continues

Explore 60 other fair value estimates on UnitedHealth Group - why the stock might be worth 24% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

A great starting point for your UnitedHealth Group research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Our free UnitedHealth Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate UnitedHealth Group's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge. Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include UNH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

UnitedHealth Group hat trotz eines großen Aufwärtskurses im Jahr bereits mehr als 30% von seinem Wert verloren, den es im Jahr 2024 gehabt hatte. Der Großteil des Unternehmens kommt aus Medicare und Medicaid. Im vergangenen Jahr war UnitedHealth Group (NYSE: UNH) ein Desaster. Es fiel stark ab, nachdem das Unternehmen höhere als erwartete Kosten von seinen Mitgliedern verzeichnete und damit zum ersten Mal seit der Finanzkrise 2008/09 die Analystenprognosen verfehlte.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Am Donnerstag, dem 16. Juli 2026, wird UnitedHealth Group (NYSE: UNH) seine zweite Quartalszahlen für das Jahr 2026 vor der Marktentfaltung veröffentlichen und eine Telefonkonferenz um 8:00 Uhr ET mit Analysten und Investoren abhalten. Diese Konferenz wird auf der Investor Relations-Seite der Website des Unternehmens (www.unitedhealthgroup.com) webcastet werden. Der Wiederspiel wird bis zum 30. Juli 2026 auf der Website verfügbar sein.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

HealthEquity, Inc. HQY is benefiting from expanding margins, improving operating leverage and technology-driven efficiency initiatives. The company is also investing in security enhancements and automation tools to strengthen customer service and fraud prevention capabilities. However, despite the improving fundamentals, HealthEquity reflects a balanced risk-reward profile.

The key question for investors is whether stronger profitability and higher guidance can outweigh ongoing exposure to custodial yield fluctuations, cybersecurity-related uncertainties and competitive pressures.

HQY’s Strong Fiscal First-Quarter Performance Supports Outlook

HealthEquity delivered adjusted earnings per share of $1.24 in the first quarter of fiscal 2027, surpassing the Zacks Consensus Estimate by 11.7%. Earnings increased 28% year over year, driven by operating leverage and continued business momentum.

Revenues rose 7% year over year to $354.6 million and modestly exceeded expectations. Growth was supported by contributions from service, custodial and interchange revenues, demonstrating broad-based strength across the business.

HQY Margin Expansion Highlights Operating Leverage

Profitability remained a key highlight during the quarter. Gross profit increased 14.3% year over year to $256.3 million, while gross margin expanded 450 basis points to 72.3%.

Although HealthEquity continued to invest in growth and technology initiatives, margin performance remained strong. Sales and marketing expenses increased 3.3% year over year to $26.8 million, technology and development expenses rose 10.3% year over year to $67.8 million, and general and administrative expenses climbed 21.9% year over year to $31.1 million. Even with these investments, operating income increased 23.9%, resulting in a 390-basis-point expansion in operating margin to 29%.Zacks Investment Research

Image Source: Zacks Investment Research

HQY’s Raised Guidance Reflects Confidence

Management raised its fiscal 2027 outlook following the strong start to the year. Revenues are now expected to be in the range of $1.41-$1.42 billion, up from the prior guidance of $1.405-$1.415 billion.

Adjusted earnings per share are now projected to be between $4.66 and $4.73 compared with the earlier range of $4.56-$4.65. The higher outlook reflects stronger participation in enhanced-rate offerings, benefits from the company's hedging strategy designed to reduce custodial yield volatility and continued operational improvements.

Solid Financial Position Supports Flexibility

HealthEquity ended the quarter with cash and cash equivalents of $265.4 million. Total debt declined to $942.6 million from $957.4 million at fiscal 2026-end, reflecting ongoing balance-sheet improvement.

Story Continues

The company's interest coverage ratio improved to 6.4 times from 5.9 times at the end of fiscal 2026. Meanwhile, operating cash flow increased significantly to $97.5 million from $64.7 million in the year-ago period, highlighting stronger cash generation and improving earnings quality.

HQY Share Repurchases and Capital Allocation

HealthEquity’s active share repurchase plan is part of the current setup and can support per-share outcomes when operating performance is also improving. Buybacks tend to matter most when they are funded by sustained cash generation and when the business outlook remains stable enough to avoid a reversal in capital priorities.

Risks Remain on the Radar

Despite the favorable operating trends, investors should continue monitoring several risk factors. HealthEquity remains sensitive to changes in custodial yields and client contract dynamics. In addition, cybersecurity-related litigation and regulatory developments continue to create uncertainty.

The company also operates in a competitive environment where larger players such as UnitedHealth Group UNH and Webster Financial WBS possess significant scale and distribution advantages.

Investment Takeaway

HealthEquity is executing well, as evidenced by expanding margins, rising cash flow and increased fiscal 2027 guidance. Management's focus on automation, fraud reduction and security enhancements is supporting profitability while positioning the business for long-term growth.

However, exposure to custodial yield fluctuations, cybersecurity overhangs and competitive pressures prevents a more aggressive stance at this stage. Consequently, HealthEquity's current Zacks Rank #3 (Hold) appears appropriate as investors await further confirmation that recent margin gains and guidance improvements can be sustained. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

HQY’s Sales & EPS Picture

In fiscal 2027, HQY is expected to experience growth of 7.8% in revenues. On the profitability front, earnings per share are expected to improve 17.8% year over year.Zacks Investment Research

Image Source: Zacks Investment Research

HQY’s Valuation Picture

HQY currently trades at a forward 12-months price-to-sales ratio of 5.2X, above its industry’s current level of 0.5X.Zacks Investment Research

Image Source: Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report

Webster Financial Corporation (WBS) : Free Stock Analysis Report

HealthEquity, Inc. (HQY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Geopolitical tensions, a surge in global oil prices and economic uncertainties, owing to rising inflation, have turned Wall Street volatile. Stocks have been suffering lately as uncertainty over an end to the war with Iran has dented investors’ confidence.

Also, hopes of a rate cut are a distant dream as the Federal Reserve has indicated a rate hike if inflation remains elevated.

Amid the ongoing uncertainty, conservative investors seeking reliable income and looking for ways to protect their capital may want to consider holding or investing in dividend-paying stocks.

Such stocks provide steady earnings through regular dividend payouts and can help mitigate the effects of market volatility. Three such stocks are: Casey's General Stores, Inc. CASY, CEMEX, S.A.B. de C.V. CX and UnitedHealth Group UNH.

Geopolitical Uncertainty, High Inflation Raise Concerns

President Donald Trump on Wednesday suggested that the Iran war is far from over as negotiations with Tehran were taking “too long.” Investors had remained hopeful for over a month that the United States and Iran could reach a peace deal soon. However, a fresh round of attacks carried out earlier this week has again proved that the ceasefire remains fragile.

Oil prices have spiked nearly 40% since the beginning of the war, leading to a surge in inflation over the past two months.

Consumer price index (CPI) climbed 0.6% in April after increasing 0.9% in March. On an annual basis, CPI was up 3.8% in April compared with the same month a year earlier, marking its highest year-over-year reading since May 2023. Economists believe inflation rose further in May.

Investors were hopeful that the Federal Reserve would go for a rate cut in the second half of the year. However, several Fed officials believe a 25-basis-point rate cut will be necessary if inflation remains above the Fed’s 2% target. A rate hike could keep markets volatile for a longer period.

3 Stocks That Recently Announced Dividend Hikes

Casey's General Stores

Casey's General Stores, Inc. operates convenience stores under the Casey's and Casey's General Store names in 16 states, mainly Iowa, Missouri and Illinois. CASY offers a comprehensive range of products and services to meet the needs of its customers. Casey’s General Stores has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

On June 9, Casey's General Stores announced that its shareholders would receive a dividend of $0.65 a share on Aug. 14. CASY has a dividend yield of 0.30%. Over the past five years, Casey's General Stores has increased its dividend six times, and its payout ratio presently sits at 13% of earnings. Check Casey's General Stores' dividend history here.

Story Continues

CEMEX

CEMEX, S.A.B. de C.V. is one of the largest cement companies in the world, with close to 78 million metric tons of production capacity. Through operating subsidiaries in four continents, CX is engaged in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates and clinker. CEMEX has a Zacks Rank #3.

On June 5, CEMEX declared that its shareholders would receive a dividend of $0.03 a share on June 29. CX has a dividend yield of 0.75%. Over the past five years, CEMEX has increased its dividend four times, and its payout ratio presently sits at 25% of earnings. Check CEMEX’s dividend history here.

UnitedHealth Group

UnitedHealth Group provides a wide range of healthcare products and services, such as health maintenance organizations, point of service plans, preferred provider organizations and managed fee-for-service programs. UNH has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages.

On June 3, UnitedHealth Group announced that its shareholders would receive a dividend of $2.32 a share on June 23. UNH has a dividend yield of 2.14%. Over the past five years, UnitedHealth Group has increased its dividend six times, and its payout ratio at present sits at 54% of earnings. Check UnitedHealth Group’s dividend history here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report

Cemex S.A.B. de C.V. (CX) : Free Stock Analysis Report

Casey's General Stores, Inc. (CASY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

In this battle of ETFs, Schwab U.S. Dividend Equity ETF (NYSEMKT:SCHD) offers a higher distribution yield and a more concentrated portfolio compared to the broader, lower-cost Vanguard High Dividend Yield ETF (NYSEMKT:VYM).

Dividend-focused investors often narrow their search to these two heavyweights. Both funds target established, dividend-paying U.S. companies, but they differ in how they screen for quality, how they weight their positions, and how much they charge for the privilege.

Snapshot (cost & size)

Metric VYM SCHD Issuer Vanguard Schwab Expense ratio 0.04% 0.06% 1-yr return (as of June 8, 2026) 24.3% 26.3% Dividend yield 2.2% 3.2% Beta 0.73 0.67 AUM $94.6 billion $95.3 billion

Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

With a 0.06% expense ratio, SCHD is competitively priced, though it sits 2 basis points above VYM at 0.04%. For income seekers, the Schwab fund compensates with a 3.2% distribution yield, notably higher than the 2.2% offered by its Vanguard peer.

Performance & risk comparison

Metric VYM SCHD Max drawdown (5 yr) (15.8%) (16.8%) Growth of $1,000 over 5 years (total return) $1,710 $1,503

Schwab U.S. Dividend Equity ETF focuses on quality and sustainability, tracking the Dow Jones U.S. Dividend 100 Index. It holds 103 stocks, making it much more concentrated than its peer. Its sector exposure tilts toward technology at 19%, with consumer defensive and healthcare both at 18%. Top holdings include Qualcomm (NASDAQ:QCOM) at 5.85%, Texas Instruments (NASDAQ:TXN) at 5.55%, and UnitedHealth Group (NYSE:UNH) at 5.40%. Stalwart stocks like Coca-Cola (NYSE:KO), Merck (NYSE:MRK), and Verizon Communications (NYSE:VZ) are also among its top 10 positions, and no single holding exceeds 6% of the portfolio. Launched in 2011, the fund has a trailing-12-month dividend payout of $1.06 per share.

Vanguard High Dividend Yield ETF casts a wider net with more than 600 holdings. It favors financial services at 20%, followed by technology at 18% and healthcare at 12%. Its largest positions include Broadcom (NASDAQ:AVGO) at 8.03%, JPMorgan Chase (NYSE:JPM) at 3.35%, and ExxonMobil (NYSE:XOM) at 2.72%. Household names like Bank of America (NYSE:BAC), Johnson & Johnson (NYSE:JNJ), and Procter & Gamble (NYSE:PG) are also among its top 10. The Vanguard fund was launched in 2006 and has paid $3.51 per share in dividends over the trailing 12 months.

Story Continues

For more guidance on ETF investing, check out the full guide at this link.

What this means for investors

The Vanguard and Schwab ETFs share many similarities, with comparable assets under management, expense ratios, and recent returns. SCHD is considerably more concentrated, but contains many blue chip names. Vanguard's ETF offers far more diversification, boasting over 600 equities. While VYM's payout is greater on a dollar basis, its yield is lower, meaning if $1,000 were invested in each fund, Schwab's ETF would ultimately generate more annual income.

Investors primarily interested in the dividend yield would probably prefer to opt for SCHD. However, VYM's diversification shouldn't be discounted; the ETF's performance is spread out over hundreds of stocks, reducing your overall risk (but also your overall potential return). Given dividend-paying stocks tend to be more stable in general, investors with a long-term time horizon would likely feel comfortable owning shares of either ETF, though SCHD's yield is clearly more attractive.

Should you buy stock in Schwab U.S. Dividend Equity ETF right now?

Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $439,038! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,277,804!

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of June 10, 2026.

JPMorgan Chase is an advertising partner of Motley Fool Money. Bank of America is an advertising partner of Motley Fool Money. Erin Kennedy has positions in Schwab U.S. Equity Dividend ETF. The Motley Fool has positions in and recommends Broadcom, JPMorgan Chase, Merck, Qualcomm, Texas Instruments, and Vanguard High Dividend Yield ETF. The Motley Fool recommends Johnson & Johnson, UnitedHealth Group, and Verizon Communications. The Motley Fool has a disclosure policy.

Schwab vs. Vanguard: Which Dividend ETF Offers a Juicier Yield? was originally published by The Motley Fool

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wall Street witnessed a rout last week on growing fears of rising rates. The tech-heavy NASDAQ 100 Index lost 4.5% last week, the S&P 500 slumped 2.6%, the Dow Jones slipped 0.3% and the Russell 2000 retreated over 2.9%.

Upbeat Job Data

Nonfarm payrolls jumped a seasonally adjusted 172,000 in May, down slightly from the upwardly revised 179,000 in April and way higher than the Dow Jones consensus estimate of 80,000, as quoted on CNBC.

The unemployment rate held steady at 4.3%, as expected. Average hourly earnings rose 0.3% for the month and were up 3.4% over the past year, both in line with the Wall Street consensus, as reported by CNBC.

Such a hot jobs report fueled Fed rate hike bets. This is especially true given that inflation reached its highest level in three years. The Personal Consumption Expenditures (PCE) Index, the central bank's preferred inflation gauge, rose 3.8% year over year in April, up from 3.5% in March and marking the highest reading in three years.

Steep Sell-Off in Chip Stocks

Chip stocks were hammered on June 5, 2026, with the semiconductor sector suffering its steepest decline since April 2025, as quoted on Yahoo Finance. The slump has erased more than $1 trillion in market value as investors rapidly unwind positions tied to the AI boom.

The divergence in the market selloff suggests this is not a full-scale market sell-off. Instead, it appears to be a concentrated unwinding of one of the market's most crowded and high-flying trades. Notably, the 10 largest decliners accounted for about $923 billion of those losses, the Yahoo article noted. Prior to this selloff, chip biggie Broadcom Inc.'s AVGO had dropped 14.2% last week due to downbeat guidance.

Winning ETFs of the Week

Breakwave Tanker Shipping ETF BWET – Up 25.5% Last Week

The Middle East conflict and the closure of the Strait of Hormuz have disrupted key shipping routes, driving a sharp surge in freight rates. This has strengthened the investment case for BWET. Broader disruptions across global trade lanes have also supported shipping stocks this year, with elevated shipping rates in recent months positioning the fund as a clear beneficiary (read: Shipping ETF (BWET) Hits New 52-Week High).

ProShares Short Ether ETF SETH – Up 25.5% Last Week

The underlying Bloomberg Ethereum Index measures the performance of a single ether traded in USD. The price of Ethereum has dropped about 22.2% last week (as of June 5, 2026). Rising rate worries have hurt this risky and volatile asset.

ProShares Short Bitcoin ETF BITI – Up 15.2% Last Week

Story Continues

The underlying Bloomberg Bitcoin Index measures the performance of a single bitcoin traded in USD. Price of Bitcoin has dropped about 15% last week (as of June 5, 2026). Higher rates and profit booking have hurt the space.

Roundhill Cannabis ETF WEED – Up 11.5% Last Week

This ETF is active and does not track a benchmark. The U.S. cannabis industry got a major boost, as the Department of Justice and the Drug Enforcement Administration proposed moving marijuana from Schedule I to Schedule III.

The change would exempt cannabis businesses from Section 280E tax restrictions, allowing them to deduct ordinary business expenses. For now, the proposal applies to medical marijuana, with hearings set for June 29 to consider extending Schedule III status to recreational cannabis as well, per Motley Fool, as quoted on Yahoo Finance.

Roundhill UNH WeeklyPay ETF UNHW – Up 8.9% Last Week

The Roundhill UNH WeeklyPay ETF seeks to pay weekly distributions and to provide calendar week returns, before fees and expenses, that correspond to 1.2 times the calendar week total return of common shares of UnitedHealth Group Incorporated. The fund charges 99 bps in fees and yields 16.14% annually.

UnitedHealth's efforts to cut costs and simplify its business are helping to boost its bottom line. The move should help its stock performance, per Bank of America, as quoted on CNBC.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Broadcom Inc. (AVGO) : Free Stock Analysis Report

Roundhill Cannabis ETF (WEED): ETF Research Reports

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quick Read

Healthcare's 901,000-job hiring surge is powering UNH up 26% and HUM up 42% YTD as aging-population demand drives insurer profits. Polymarket prices an 80% chance of zero 2026 rate cuts, an environment where JPM's record revenue and O's 5% yield both thrive. It sounds nuts, but SoFi is giving new active invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for yourself (Sponsor)

Economist Justin Wolfers dropped a number on the Prof G Markets podcast that should reorganize how you think about the 2026 economy. Since Trump took office, healthcare and social services has added roughly 901,000 jobs, while every other part of the economy has actually lost jobs on net. One sector hiring. Everything else shedding.

Before we mortgage the house on hospital REITs, Wolfers offered an honest caveat. He warned the finding may be "somewhat less relevant than it sounds" because overall job creation is naturally low thanks to weak population growth: "The closer you are to the whole not growing very much, the more likely it is you'll end up in a world in which one sector's doing all the positive and everything else is a negative." In other words, slow-growth arithmetic flatters whichever sector happens to be expanding.

Still, the labor data is real. Total nonfarm payrolls reached 159,001 thousand in May 2026, with unemployment steady at 4.3%. I have been reading every jobs report for the better part of a decade, and the divergence between healthcare and everything else is the most lopsided I can remember outside of a recession.

Why Wall Street Hated the NewsPublic Domain / Wikimedia Commons

Wolfers explained the paradox simply: investors are playing "the game of Federal Reserve." Strong jobs mean the Fed has no reason to rescue the labor market with rate cuts, while core PCE keeps grinding higher (the index hit 129.63 in April). Polymarket now prices zero rate cuts in 2026 at roughly 80% probability, with the funds rate parked at 3.75% since January and the 10-year Treasury at 4.56%.

That means we'll likely continue a cycle of more job growth in healthcare while rates remain elevated. This impacts two primary sectors.

SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.

Where the Hiring Is Showing Up in Stocks

UnitedHealth Group (NYSE:UNH) just posted Q1 2026 adjusted EPS of $7.23 against a $6.61 estimate, with the medical cost ratio tightening 90 basis points to 83.9%. The stock is up 26% year to date.

Story Continues

Humana (NYSE:HUM) is the comeback story, up 42% YTD despite a brutal Star Ratings headwind that crushed FY2026 adjusted EPS guidance to at least $9.00 from $17.14 in 2025. Individual Medicare Advantage membership is up roughly 22% year to date. CVS Health (NYSE:CVS) raised FY2026 adjusted EPS guidance to $7.30 to $7.50 after Aetna's medical benefit ratio improved to 84.6% from 87.3%.

The Other Side: Rates Stay High With Financial Tailwinds

JPMorgan Chase (NYSE:JPM) just reported Q1 2026 net income of $16.49 billion with markets revenue at a record $11.60 billion. Jamie Dimon called the economy "resilient" while flagging risks ranging from trade uncertainty to elevated asset prices.

Realty Income (NYSE:O) is up 11% YTD and yields over 5%, with Q1 AFFO per share growing 6.6% and investment volume guidance raised to $9.5 billion at 7.1% cash yields. Sumit Roy is deploying capital as if rates will stay where they are, which Polymarket says is the right bet.

The Frame for Your Portfolio

Wolfers' caveat matters, but the investing implication holds either way. If you believe the labor market keeps printing healthcare jobs while the Fed stays parked, the defensive sleeve with real demand (the insurers and pharmacy chains serving an aging population) makes sense, the bank earning a fat net interest margin makes sense, and a net-lease REIT that already underwrote 7%+ yields makes sense. The next signal to watch is the June 16 to 17 FOMC meeting and the next core PCE report. If inflation reaccelerates, the conversation shifts from "no cuts" to "possible hikes," and the math on every dividend stock changes overnight.

Want Up To $1,000? SoFi Is Giving New Active Invest Users Free Stock

Looking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.

From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you're just starting or already experienced. Its easy to sign up and secure your bonus.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

It looks like UnitedHealth Group Incorporated (NYSE:UNH) is about to go ex-dividend in the next four days. Typically, the ex-dividend date is one business day before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is important as the process of settlement involves a full business day. So if you miss that date, you would not show up on the company's books on the record date. Accordingly, UnitedHealth Group investors that purchase the stock on or after the 15th of June will not receive the dividend, which will be paid on the 23rd of June.

The company's upcoming dividend is US$2.32 a share, following on from the last 12 months, when the company distributed a total of US$8.84 per share to shareholders. Looking at the last 12 months of distributions, UnitedHealth Group has a trailing yield of approximately 2.1% on its current stock price of US$413.00. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. As a result, readers should always check whether UnitedHealth Group has been able to grow its dividends, or if the dividend might be cut.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. UnitedHealth Group is paying out an acceptable 67% of its profit, a common payout level among most companies. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Fortunately, it paid out only 41% of its free cash flow in the past year.

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

See our latest analysis for UnitedHealth Group

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.NYSE:UNH Historic Dividend June 10th 2026

Have Earnings And Dividends Been Growing?

Companies with falling earnings are riskier for dividend shareholders. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. That's why it's not ideal to see UnitedHealth Group's earnings per share have been shrinking at 4.0% a year over the previous five years.

Story Continues

Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Since the start of our data, 10 years ago, UnitedHealth Group has lifted its dividend by approximately 16% a year on average. Growing the dividend payout ratio while earnings are declining can deliver nice returns for a while, but it's always worth checking for when the company can't increase the payout ratio any more - because then the music stops.

The Bottom Line

Is UnitedHealth Group worth buying for its dividend? We're not enthused by the declining earnings per share, although at least the company's payout ratio is within a reasonable range, meaning it may not be at imminent risk of a dividend cut. Overall, it's hard to get excited about UnitedHealth Group from a dividend perspective.

However if you're still interested in UnitedHealth Group as a potential investment, you should definitely consider some of the risks involved with UnitedHealth Group. To help with this, we've discovered 2 warning signs for UnitedHealth Group that you should be aware of before investing in their shares.

A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

UnitedHealth Group Incorporated (NYSE:UNH) is included among the 10 Best Dividend Stocks to Buy According to D. E. Shaw.Mizuho Boosts UnitedHealth (UNH) Target as Managed Care Outlook Improves

On June 8, Mizuho raised its price recommendation on UnitedHealth Group Incorporated (NYSE:UNH) to $460 from $440. It reiterated an Outperform rating on the shares. The firm said it believes the managed care sector is moving into a "more stable and predictable" policy environment. In a research note, the analyst stated that the size and frequency of policy-related surprises are likely to ease from the elevated levels seen over the past three years. That shift could allow investors to focus more on company fundamentals, pricing recovery, and the sector's underlying earnings power. Mizuho also increased price targets across the managed care sector to reflect what it sees as a more stable regulatory and legislative backdrop.

On June 4, Morgan Stanley analyst Erin Wright raised the firm's price target on UNH to $453 from $395 while maintaining an Overweight rating on the stock. The analyst noted that managed care stocks have been "grinding higher" amid early signs of softer utilization trends. Wright also examined the potential benefits of artificial intelligence for managed care organizations, saying AI could create tailwinds across both revenue and cost areas. As those efficiencies scale, the firm estimates they could generate about 45% average EPS upside.

UnitedHealth Group Incorporated (NYSE:UNH) is a healthcare and well-being company. Its business segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which consists of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, and UnitedHealthcare Community & State.

While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 10 Most Profitable Dividend Stocks to Invest In Now and Billionaire Ken Fisher's Top 11 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

View Comments